secwatch / observer
8-K filed October 8, 2024, 7:59 PM ET ticker OKUR CIK 0001637715
M&A confidence high sentiment neutral materiality 1.00

OnKure completes reverse merger with Reneo; trades as OKUR with $65M PIPE

OnKure Therapeutics, Inc.

item 2.01item 3.02item 9.01item 3.03item 5.01item 5.02item 5.03item 5.05item 5.06item 7.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Isaac Manke

Class I Director
OKUR · OnKure Therapeutics, Inc.
Effective
2024-10-04
Filed
October 8, 2024, 7:59 PM ET
Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.
Appointed

Andrew Phillips

Chair of the Board
OKUR · OnKure Therapeutics, Inc.
Effective
2024-10-04
Filed
October 8, 2024, 7:59 PM ET
Also on October 4, 2024, Andrew Phillips, Ph.D. was appointed as the Chair of the Board.
Appointed

Edward T. Mathers

Class II Director
OKUR · OnKure Therapeutics, Inc.
Effective
2024-10-04
Filed
October 8, 2024, 7:59 PM ET
Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.
Appointed

Nicholas Saccomano

Class I Director
OKUR · OnKure Therapeutics, Inc.
Effective
2024-10-04
Filed
October 8, 2024, 7:59 PM ET
Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.
Appointed

Andrew Phillips

Class III Director
OKUR · OnKure Therapeutics, Inc.
Effective
2024-10-04
Filed
October 8, 2024, 7:59 PM ET
Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.
Appointed

R. Michael Carruthers

Class II Director
OKUR · OnKure Therapeutics, Inc.
Effective
2024-10-04
Filed
October 8, 2024, 7:59 PM ET
Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.
Appointed

Valerie M. Jansen

Class II Director
OKUR · OnKure Therapeutics, Inc.
Effective
2024-10-04
Filed
October 8, 2024, 7:59 PM ET
Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.
Appointed

Michael Grey

Class III Director
OKUR · OnKure Therapeutics, Inc.
Effective
2024-10-04
Filed
October 8, 2024, 7:59 PM ET
Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Isaac Manke was appointed as Class I Director at OnKure Therapeutics, Inc..

Action
appointed
Role
Class I Director
Exact text from the filing
Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Andrew Phillips was appointed as Chair of the Board at OnKure Therapeutics, Inc..

Action
appointed
Role
Chair of the Board
Exact text from the filing
Also on October 4, 2024, Andrew Phillips, Ph.D. was appointed as the Chair of the Board.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Edward T. Mathers was appointed as Class II Director at OnKure Therapeutics, Inc..

Action
appointed
Role
Class II Director
Exact text from the filing
Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Nicholas Saccomano was appointed as Class I Director at OnKure Therapeutics, Inc..

Action
appointed
Role
Class I Director
Exact text from the filing
Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Andrew Phillips was appointed as Class III Director at OnKure Therapeutics, Inc..

Action
appointed
Role
Class III Director
Exact text from the filing
Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

R. Michael Carruthers was appointed as Class II Director at OnKure Therapeutics, Inc..

Action
appointed
Role
Class II Director
Exact text from the filing
Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Valerie M. Jansen was appointed as Class II Director at OnKure Therapeutics, Inc..

Action
appointed
Role
Class II Director
Exact text from the filing
Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Grey was appointed as Class III Director at OnKure Therapeutics, Inc..

Action
appointed
Role
Class III Director
Exact text from the filing
Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.
View on SEC.gov
Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

OnKure Therapeutics, Inc.: Adoption of a new Code of Business Conduct and Ethics applicable to all employees, officers and directors.

Change
code of ethics
Exact text from the filing
In connection with the Transactions, the Board approved and adopted a new Code of Business Conduct and Ethics applicable to all employees, officers and directors of the Company.
View on SEC.gov
Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

OnKure Therapeutics, Inc.: Amended and restated certificate of incorporation to change name to OnKure Therapeutics, Inc., create Class B Common Stock, reclassify Reneo common stock as Class A Common Stock (effective 2024-10-04).

Change
charter amendment
Effective
2024-10-04
Exact text from the filing
The amended and restated certificate of incorporation became effective at 4:02 p.m. on October 4, 2024.
View on SEC.gov
Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

OnKure Therapeutics, Inc.: Amendment and restatement of bylaws updating stockholder meeting procedures, director nomination requirements, board meeting provisions, indemnification, and other updates (effective 2024-10-04).

Change
bylaw amendment
Effective
2024-10-04
Exact text from the filing
On October 4, 2024, in connection with the Merger, the Board approved the amendment and restatement of the Company’s bylaws, effective as of October 4, 2024
View on SEC.gov
Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

OnKure Therapeutics, Inc.: Reneo ceased to be a shell company as a result of the Transactions.

Change
shell status
Exact text from the filing
As a result of the Transactions, Reneo ceased to be a shell company (as defined in Rule 12b-2 of the Exchange Act) upon the Closing.
View on SEC.gov

27 governance changes filed in the last 30 days. Browse all governance changes →

OnKure Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-24-234487
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.